The phase II randomized, open label, parallel assignment, safety/efficacy study is currently recruiting approximately 26 participants. The study principal investigator is Michael McGuire, DDS Perio Health Professionals, PLLC.
CelTx is a cellular construct, designed to deliver living cells to regenerate soft tissue in the mouth. CelTx contains and produces cytokines and growth factors to stimulate the patient’s own cells to regenerate new, healthy tissue. The product is constructed based on apligraf technology.
